Pharmaceutical manufacturing facility
WHO Prequalified · Est. 2013 · Nairobi, Kenya

Manufacturing Medicines
Africa Can Rely On

East and Central Africa's most accredited pharmaceutical manufacturer — producing 1.3 billion units per year from our state-of-the-art GMP facility in Nairobi's Industrial Area.

Explore capabilities Partner with us
🏭
1.3B+
Units manufactured per year
🌍
Only
WHO-PQ ARV site in Central & East Africa
100+
3
Active GMP certifications — valid to 2027
PPB Kenya
TMDA Tanzania
EAC NMRAs
WHO Prequalified
Approved by
PPB Kenya GMP · Valid Apr 2027
TMDA Tanzania · Valid Jun 2027
EAC NMRAs · Valid Jun 2027
WHO Prequalified · Since 2017
Mankind Pharma CMO · Since Sept 2024
1B
Tablets per year
Coated & uncoated
300M
Capsules per year
Hard gelatin
30M
Syrup bottles per year
Oral liquid dosages
30M
Cream tubes per year
Topical preparations
Questa Care manufacturing facility Nairobi
2013
Established
100+
Employees
2022
Facility upgraded
About Questa Care
First & Only in Central & East Africa WHO Geneva Prequalified ARV Manufacturer · Since 2017

Built for Africa. Certified for the world.

Questa Care Limited was incorporated in 2013 as the manufacturing arm of the Surgilinks Group, established with a clear purpose: to develop and manufacture high-quality pharmaceutical products for Africa — on African soil, under internationally recognised standards, at prices that reflect the continent's realities.

Our facility at Homabay Road, Industrial Area, Nairobi was comprehensively upgraded in 2022 with fully automated production lines across four dosage form categories. Today we employ over 100 pharmaceutical professionals and hold active GMP certifications from PPB Kenya, TMDA Tanzania, and the East African Community NMRAs — alongside our defining WHO Geneva prequalification.

We work as a long-term manufacturing partner for some of the world's leading pharmaceutical companies — Glenmark, Mankind Pharma, Intas, and Mylan/Viatris — producing registered products for markets across East and Central Africa.

Manufacturing capabilities

Four dosage forms. One standard: GMP.

Every product manufactured at our Nairobi facility meets WHO GMP, PPB Kenya, and EAC NMRA requirements — with batch-level traceability from raw material to finished goods release.

Pharmaceutical tablet manufacturing
Oral Solid
1B
units / year
Tablets & Capsules
Coated and uncoated tablets, hard gelatin capsules — non-hormonal, non-cytotoxic. Full granulation, compression, coating, encapsulation, and blister packaging in-house.
Film-coated tablets Hard gelatin capsules Blister packaging
Pharmaceutical liquid manufacturing
Oral Liquid
30M
bottles / year
Syrups & Suspensions
Oral syrups, suspensions, and solutions for general pharmaceutical and human-category applications. Dedicated liquid manufacturing suites with in-line quality checks.
Oral syrups Suspensions Oral solutions
Cream and ointment manufacturing
Topical
30M
tubes / year
Creams & Ointments
Topical preparations for dermatological and specialised therapeutic use. Full manufacturing, primary tube filling and sealing, and quality control all conducted in-house.
Dermatological creams Ointments Tube filling
Contract manufacturing pharmaceutical
CMO Services
4+
global partners
Contract Manufacturing
Technology transfer, formulation development, registered product manufacturing, and packaging for global pharmaceutical partners. Approved CMO for Glenmark, Mankind Pharma, Intas, and Mylan/Viatris.
Tech transfer Formulation dev Regulatory dossiers
Quality & Compliance

Every batch. Every test. No exceptions.

At Questa Care, quality is not a department — it is the operating principle of the entire organisation. We hold three simultaneous active GMP certifications and have maintained a zero-deviation record on all regulatory inspections.

PPB Kenya — GMP Certificate
Cert. No. PPB/INS/GMP/FPP/CERT/124/25 · Inspected Jan 2024
✓ Valid to April 2027
TMDA Tanzania — GMP Certificate
Cert. No. TAN 0025 D/GMP 0001 · Issued July 2024
✓ Valid to June 2027
EAC NMRAs — GMP Certificate
Cert. No. 088/GMP/2024 · Issued July 2024
✓ Valid to June 2027
Quality control laboratory pharmaceutical
🔬
QC Laboratory
Instrumentation, chemical, stability, microbiology, and packaging material testing sections.
📋
Full Documentation
SOPs governing every activity. Batch manufacturing records with complete traceability.
🌡️
Stability Testing
ICH-guideline chambers for accelerated and long-term stability studies.
🛡️
Pharmacovigilance
Active adverse event monitoring and reporting for all marketed products.
Research laboratory
A historic milestone

The first & only WHO-prequalified ARV manufacturer in Central & East Africa

In 2017, Questa Care received WHO Geneva prequalification to manufacture antiretroviral (ARV) medicines for HIV/AIDS treatment — under a Technology Transfer Agreement with Mylan/Viatris Laboratories. WHO Prequalification is the standard required by PEPFAR, the Global Fund, and UNICEF for pharmaceutical procurement.


We are the only pharmaceutical manufacturer in Central and East Africa to hold this distinction — and we are building on it. Our next milestone is WHO prequalification for the critical triple-combination ARV tablet: Dolutegravir + Lamivudine + Tenofovir (DTG/3TC/TDF).

ARV HIV medicine research Africa
2013
Questa Care incorporated as manufacturing arm of Surgilinks Group. Operations commence at Homabay Road, Nairobi.
2017
WHO Geneva prequalification achieved. First & only such site in Central & East Africa. Tech Transfer with Mylan/Viatris.
2022
New state-of-the-art GMP facility commissioned. Annual capacity exceeds 1.3 billion units across all dosage forms.
2024
PPB Kenya, TMDA Tanzania & EAC NMRAs all renewed. Mankind Pharma CMO approval granted in September.
Next
WHO PQ for DTG+3TC+TDF combination ARV tablet. Pan-African expansion across all 8 EAC states.
Therapeutic areas

The medicines Africa needs most

Our product portfolio and contract manufacturing capabilities span 12 therapeutic categories — covering the most significant disease burden across Sub-Saharan Africa.

💊
ARVs — HIV/AIDS
WHO-prequalified. DTG/3TC/TDF PQ in progress.
🦠
Antibacterial
Oral solid and liquid forms across multiple classes.
🫁
Antifungal
Oral and topical formulations.
❤️
Cardiovascular
Tablet formulations across multiple indications.
🔥
Anti-inflammatory
Oral and topical — broad portfolio.
🧠
Antiepileptic
Standard and controlled-release tablet forms.
🌸
Obstetrics & Gynaecology
Range of registered products.
💧
Urology
Oral solid dosage forms.
🤢
Antiemetics
Oral solid and liquid dosage forms.
🌬️
Antihistamines
Tablet and syrup formulations.
⚗️
Antimuscarinics
Oral solid dosage forms.
💧
Antidiuretics
Tablet formulations.
Key partners & clients

Trusted by global pharmaceutical leaders

We are an approved contract manufacturer for leading global pharmaceutical companies and a certified supplier to government and NGO health programmes across Africa.

Glenmark Pharmaceuticals
Flagship partner — oncology, dermatology & respiratory. Contract manufacturing & supply partnership.
$20M+ portfolio
Mylan / Viatris Laboratories
WHO-prequalified ARV manufacturing partner since 2017. Technology Transfer Agreement.
Strategic
Mankind Pharma
Approved CMO since September 2024. Antibacterial, dermatology & OTC product categories.
CMO Approved 2024
Intas Pharmaceuticals
Strategic API and finished dose collaboration. API and finished formulations developed and registered.
Strategic Partner
PS Kenya
Government & NGO health programme supply. Critical medicines for national health facilities.
Government Supply
MEDS
Mission for Essential Drugs & Supplies. Certified supply to mission hospitals across East Africa.
NGO Supply
PEPFAR
Eligible ARV supplier via WHO prequalification. Critical HIV treatment supply to national programmes.
WHO PQ Eligible
The Global Fund
WHO-prequalified supplier eligible for Global Fund and UNICEF procurement programmes.
WHO PQ Eligible
R&D Pipeline

Formulating Africa's most needed medicines

Our R&D and regulatory affairs team works at the intersection of pharmaceutical science and African health priorities — developing new formulations, managing technology transfers, and building a pipeline targeted at the continent's highest disease burden.

Our capabilities include technology transfer management, formulation development for all four dosage forms, ICH-guideline stability studies, CTD dossier preparation for PPB Kenya, TMDA, EAC NMRAs, and WHO PQP, and post-approval variation management.

WHO Prequalification — In Progress
Dolutegravir + Lamivudine + Tenofovir
Fixed-Dose Combination Tablet · DTG/3TC/TDF
The global WHO-recommended first-line HIV treatment — combining three active pharmaceutical ingredients into a single daily tablet. Listed on the WHO Essential Medicines List. Achieving WHO PQ for this product qualifies it for procurement by PEPFAR, the Global Fund, and UNICEF for national HIV programmes across Africa.
Active: WHO Prequalification Programme application in progress
Contact us

Partner with East Africa's leading pharmaceutical manufacturer

Whether you need a GMP-certified CMO, registered product supply, tender programme support, or a co-development partner — our team will respond within two working days.

Head Office & Plant Plot 71/281, Gate 19, Homabay Road
Industrial Area, Nairobi, Kenya
P.O. Box 172-00623
Email rohan.kothari@questacareltd.com
info@questacareltd.com
Phone +254 735 693 636
+254 713 656 303
Website www.questacareltd.com
Global centres: Delaware, USA · Vadodara, India

Send an enquiry

Our team responds within two working days.